Literature DB >> 24984273

The depressogenic-like effect of acute and chronic treatment with dexamethasone and its influence on the activity of antidepressant drugs in the forced swim test in adult mice.

Andrzej Wróbel1, Anna Serefko2, Piotr Wlaź3, Ewa Poleszak4.   

Abstract

There is a close relationship between chronic stress, glucocorticoids and depression. Psychiatric and cognitive symptoms resembling major depression have been observed in patients experiencing elevated glucocorticoid levels, and a high percentage of people suffering from depression have undergone a stressful event/events prior to the onset of this mental disorder. In our study, we investigated whether acute and chronic treatment of dexamethasone induces depression-like behavior in mice and if dexamethasone therapy influences the activity of antidepressant drugs with diverse modes of action. The antidepressant-like effect was assessed by the forced swim test in adult mice. The depressogenic-like activity of dexamethasone turned out to be dose-dependent: only the highest tested dose of the glucocorticoid (i.e., 64μg/kg) given as a single injection increased immobility time, whereas 16μg/kg/day of dexamethasone (but not 4μg/kg/day) administered repeatedly induced a significant alteration in animal behavior. These depressogenic doses of dexamethasone (i.e., 64μg/kg and 16μg/kg/day for an acute and repeated administration, respectively) diminished the antidepressant potential of the therapeutic doses of imipramine (10mg/kg), amitriptyline (10mg/kg), tianeptine (25mg/kg), mianserin (10mg/kg), citalopram (15mg/kg) and moclobemide (25mg/kg). Two main findings of our study should be particularly underlined: (1) both single and repeated administration of dexamethasone evoked a depression-like behavior of mice, (2) both single and repeated administration of dexamethasone were able to modify the activity of the antidepressant agents from various pharmacological groups, which may lead to a considerable reduction in the efficacy of pharmacotherapy prescribed for patients with mood disorders.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antidepressant-like activity; Dexamethasone; Forced swim test; Mice

Mesh:

Substances:

Year:  2014        PMID: 24984273     DOI: 10.1016/j.pnpbp.2014.06.008

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  8 in total

Review 1.  Optimizing functional outcome endpoints for stroke recovery studies.

Authors:  Mustafa Balkaya; Sunghee Cho
Journal:  J Cereb Blood Flow Metab       Date:  2019-09-14       Impact factor: 6.200

2.  Glia- and tissue-specific changes in the Kynurenine Pathway after treatment of mice with lipopolysaccharide and dexamethasone.

Authors:  Carlos R Dostal; Nicolaus S Gamsby; Marcus A Lawson; Robert H McCusker
Journal:  Brain Behav Immun       Date:  2017-12-11       Impact factor: 7.217

3.  Rescuing cones and daylight vision in retinitis pigmentosa mice.

Authors:  Viviana Guadagni; Martina Biagioni; Elena Novelli; Paolo Aretini; Chiara Maria Mazzanti; Enrica Strettoi
Journal:  FASEB J       Date:  2019-06-14       Impact factor: 5.191

4.  Blockade of nociceptin/orphanin FQ signaling facilitates an active copying strategy due to acute and repeated stressful stimuli in mice.

Authors:  Victor A D Holanda; Matheus C Oliveira; Edilson D Da Silva Junior; Girolamo Calo'; Chiara Ruzza; Elaine C Gavioli
Journal:  Neurobiol Stress       Date:  2020-10-05

5.  Chronic clomipramine treatment reverses depressogenic-like effects of a chronic treatment with dexamethasone in rats.

Authors:  Abderrahim Laaziz; Hicham El Mostafi; Aboubaker Elhessni; Tarik Touil; Hanane Doumar; Abdelhalem Mesfioui
Journal:  IBRO Neurosci Rep       Date:  2022-08-01

6.  The effect of imipramine, ketamine, and zinc in the mouse model of depression.

Authors:  Andrzej Wróbel; Anna Serefko; Piotr Wlaź; Ewa Poleszak
Journal:  Metab Brain Dis       Date:  2015-07-10       Impact factor: 3.584

7.  RGD(F/S/V)-Dex: towards the development of novel, effective, and safe glucocorticoids.

Authors:  Xueyun Jiang; Ming Zhao; Yuji Wang; Haimei Zhu; Shurui Zhao; Jianhui Wu; Yuanbo Song; Shiqi Peng
Journal:  Drug Des Devel Ther       Date:  2016-03-08       Impact factor: 4.162

8.  Reduction in and Preventive Effects for Oral-Cancer Risk with Antidepressant Treatment.

Authors:  Chia-Min Chung; Tzer-Min Kuo; Kun-Tu Yeh; Chien-Hung Lee; Ying-Chin Ko
Journal:  J Pers Med       Date:  2021-06-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.